1795 — Lotus Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual cashflow statement for Lotus Pharmaceutical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	1,304	1,870	3,940	5,103	6,360
Depreciation
Amortisation
Non-Cash Items	714	806	485	194	545
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-779	-3,316	-1,643	-4,893	-2,033
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	1,949	120	3,719	1,614	6,155
Capital Expenditures	-1,998	-1,616	-3,069	-3,275	-1,466
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	873	38.9	-1,587	25.7	-1,225
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-1,125	-1,577	-4,656	-3,249	-2,691
Financing Cash Flow Items	-2,429	558	-558	0	-0.312
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-545	1,663	1,262	1,403	714
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	212	116	378	-213	4,259